GOV Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Consumable RevenueThe disposable pod model links revenue to recurring patient usage rather than one-time equipment sales. This can improve visibility, support customer retention, and create a durable revenue base as the installed Omnipod population expands over the coming quarters.
Strong Growth OutlookManagement’s outlook indicates that Insulet expects rapid expansion to continue while earnings grow faster than revenue. Sustained double-digit growth, supported by Omnipod adoption, can strengthen operating leverage and fund continued investment in the platform.
Margin ExpansionHigher gross and operating margins show that scale and manufacturing productivity are translating into stronger profitability. If these gains persist, Insulet should have greater flexibility to invest in innovation, customer access, and capacity while expanding earnings.
Bears Say
Type 2 Retention ExecutionWeak onboarding and first-90-day retention among type 2 customers could reduce the lifetime value of new starts and make growth less efficient. Insulet is implementing corrective actions, but execution must improve before this segment becomes a dependable growth contributor.
Uneven Free Cash Flow ConversionInsulet generates meaningful operating cash, but uneven conversion from earnings to free cash flow reduces the predictability of internally funded investment. Continued capital spending and weaker cash growth could constrain flexibility even while reported profitability remains strong.
Net Margin VolatilityThe large swings in net margin indicate that earnings below the gross-profit line have not yet been consistently stable. This volatility makes long-term profit conversion harder to forecast and could offset some of the benefits from strong revenue growth and operating-margin expansion.
Insulet News
GOV FAQ
What was Insulet’s price range in the past 12 months?
Currently, no data Available
What is Insulet’s market cap?
Insulet’s market cap is CHF8.02B.
When is Insulet’s upcoming earnings report date?
Insulet’s upcoming earnings report date is Oct 29, 2026 which is in 38 days.
How were Insulet’s earnings last quarter?
Insulet released its earnings results on Aug 05, 2026. The company reported CHF1.35 earnings per share for the quarter, beating the consensus estimate of CHF1.194 by CHF0.156.
Is Insulet overvalued?
According to Wall Street analysts Insulet’s price is currently Undervalued.
Does Insulet pay dividends?
Insulet does not currently pay dividends.
What is Insulet’s EPS estimate?
Insulet’s EPS estimate is 1.29.
How many shares outstanding does Insulet have?
Insulet has 69,354,200 shares outstanding.
What happened to Insulet’s price movement after its last earnings report?
Insulet reported an EPS of CHF1.35 in its last earnings report, beating expectations of CHF1.194. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Insulet?
Currently, no hedge funds are holding shares in CH:GOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insulet Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF136.25 (― Upside)
CHF136.25 (― Upside)
Blogger Sentiment
Bullish
CH:GOV Sentiment 64%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.84%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.77%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
GOV Company Deck
GOV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive operational and financial performance — strong revenue, significant margin expansion, robust EPS growth, international strength, product and clinical progress, and solid liquidity — while transparently acknowledging a meaningful, addressable execution issue in onboarding and retaining type 2 customers that led to a modest downward revision to U.S. revenue outlook and a reassessment of longer-term assumptions. Management presented concrete actions (expanded customer care, sales compensation changes, sampling refinements, Omnipod Discover and data platform investments) to remediate retention and utilization in the first 90 days and expressed confidence these will translate into improved outcomes over time.View all CH:GOV earnings summariesGOV Revenue Breakdown
70.89% U.S. Omnipod
27.85% International Omnipod
1.26% Drug Delivery
GOV Stock 12 Month Forecast
Average Price Target
―Abbott Laboratories
―
Dexcom
―
Medtronic
―
Tandem Diabetes Care
―
Beta Bionics, Inc.
―